Defining the optimal threshold and prognostic utility of pre-treatment hemoglobin level as a biomarker for survival outcomes in head and neck cancer patients receiving chemoradiation.
Ma SJ, Yu H, Khan M, Yu B, Santhosh S, Chatterjee U, Gill J, Iovoli A, Farrugia M, Wooten K, Gupta V, McSpadden R, Kuriakose MA, Markiewicz MR, Al-Afif A, Hicks WL Jr, Platek ME, Seshadri M, Ray AD, Repasky E, Singh AK.
Ma SJ, et al. Among authors: wooten k.
Oral Oncol. 2022 Oct;133:106054. doi: 10.1016/j.oraloncology.2022.106054. Epub 2022 Aug 5.
Oral Oncol. 2022.
PMID: 35933937
Free PMC article.